MEDIA CENTER

MEDIA CENTER2018-11-19T17:53:23-06:00

Latest news from Rapha Capital Management & our portfolio companies

AsclepiX Therapeutics
AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD

  • AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides for cancer, adds Steven Altschuler, MD to Board of Directors.
  • Dr. Altschuler, the founder and Chairman of the Board of Spark Therapeutics Inc. (NASDAQ: ONCE), brings to AsclepiX a deep knowledge and experience in developing novel therapies for the treatment of retinal disease.
March 25, 2019

AsclepiX Therapeutics
AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina

  • AXT107 exhibited a dual mechanism of action as a monotherapy, disrupting a key component of the Vascular Endothelial Growth Factor (VEGF) signaling pathway while also activating the Tie2 pathway that is integral to maintenance of vascular homeostasis.
  • A single monotherapy injection of AXT107 demonstrated in vivo efficacy lasting for many months, suggesting patients may require only 1 to 2 injections per year.
  • To date, AXT107 has demonstrated excellent safety, superior efficacy and longer durability in in vivo models compared to current standard of care treatments.
March 18, 2019